2.31%C 7.40 5.37%QQQQ 27.81 2.83%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
CAMBRIDGE, Mass. - Biotechnology company Molecular Insight Pharmaceuticals Inc. on Monday added four new directors to its board, including employees of GlaxoSmithKline PLC and Novartis AG.
The company named David Epstein, Dr. Yvonne Greenstreet, Joseph Limber and Dr. Anthony Martin to the board. Epstein is president and chief executive of Novartis Oncology, and Greenstreet is senior vice president and chief of research and development strategy for GlaxoSmithKline.
Limber is president and CEO of Prometheus Laboratories, Inc., a specialty pharmaceutical and diagnostics company. Martin is a founder and managing partner of TMA Consultants, which offers consulting and management services to biotechnology and life sciences companies.
In morning trading, Molecular Insight stock slipped 5 cents to $8.50.
U.S. stocks were mixed on Thursday after retailers reported mostly disappointing sales while other big-name companies announced layoffs and Europ...
China markets opened lower on Tuesday morning as the investors' confidence hit by the signals that global recession are deepening.
The markets have spoken: risk aversion is still the name of the game and that was obvious since the beginning of the week.
Building your business and corporate credit for your small business.
Get your next web design project done with our los angeles web design team - Best web design with great price.
Baldwin Linguas:
Translations Interpreting Localization:
English French Portuguese Spanish
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
0.12
-0.64
